Organizing Committee Cochairs:
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
James H. Doroshow, National Cancer Institute, Bethesda, MD
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

Scientific Committee Cochairs:
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
James L. Gulley, National Cancer Institute, Bethesda, MD
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

Scientific Committee Members:

**AACR:**
Prasad S. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, NY
Nilofer S. Azad, Johns Hopkins University, Baltimore, MD
John C. Byrd, University of Cincinnati, Cincinnati, OH
Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
Maximilian Diehn, Stanford University, Stanford, CA
Jeffrey A. Engelman, Treeline Biosciences, Watertown, MA
Susan M. Galbraith, AstraZeneca, Cambridge, England
Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada
Jonathan Hirsch, Syapse, Palo Alto, CA
David M. Hyman, Loxo Oncology at Lilly, Stamford, CT
Nada Jabado, McGill University, Montréal, QC, Canada
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Marina Y. Konopleva, The University of Texas MD Anderson Cancer Center, Houston, TX
Brigette B. Ma, Chinese University of Hong Kong, Hong Kong
Zoran Rankovic, St. Jude Children's Research Hospital, Memphis, TN
Antoni Ribas, University of California Los Angeles (UCLA), Jonsson Comprehensive Cancer Center (JCCC), Los Angeles, CA
William R. Sellers, Broad Institute, Cambridge, MA
Alexandra Snyder Charen, Merck & Co., Inc., Rahway, NJ

**NCI:**
Alice P. Chen, National Cancer Institute, Bethesda, MD
Peter L. Choyke, National Cancer Institute, Bethesda, MD
James H. Doroshow, National Cancer Institute, Bethesda, MD
Marc S. Ernstoff, National Cancer Institute, Bethesda, MD
William D. Figg, National Cancer Institute, Bethesda, MD
Lyndsay N. Harris, National Cancer Institute, Rockville, MD
Toby T. Hecht, National Cancer Institute, Rockville, MD
S. Percy Ivy, National Cancer Institute, Bethesda, MD
Stanley Lipkowitz, National Cancer Institute, Bethesda, MD
Jeffrey A. Moscow, National Cancer Institute, Bethesda, MD
Barry R. O'Keefe, National Cancer Institute, Frederick, MD
Eytan Ruppin, National Cancer Institute, Bethesda, MD
Beverly A. Teicher, National Cancer Institute, Bethesda, MD
Carole J. Thiele, National Cancer Institute, Bethesda, MD
John J. Wright, National Cancer Institute, Rockville, MD

EORTC:
Dereck D. Amakye, Bayer HealthCare, Leverkusen, Germany
Ahmad Awada, Institut Jules Bordet, Brussels, Belgium
Jan Bussink, Radboud University Medical Center, Nijmegen, Netherlands
George Coukos, UNIL University of Lausanne, Lausanne, Switzerland
Kapil Dhingra, KAPital Consulting LLC, Sparta, NJ
Elena Garralda, Vall D'Hebron Institute of Oncology, Barcelona, Spain
Ioannis Gounaris, Merck-Serono Ltd., Feltham, United Kingdom
Viktor Grünwald, Hannover Medical School, Hannover, Germany
Egesta Lopci, Istituto Clinico Humanitas, Milan, Italy
Christophe Massard, Princess Máxima Center for Pediatric Oncology, Villejuif, France
Eric Raymond, Paris Saint-Joseph Hospital, Paris, France
Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
Jaap Verweij, Cancer Drug Development Forum, Brussels, Belgium
Mike Waring, Northern Institute for Cancer Research, Newcastle upon Tyne, England

1 - Executive Committee Member

* - short-talk from highly rated proffered paper

Poster Sessions will be available on-demand throughout the entire meeting, releasing at 9:00 am ET on Day 1, except those in the press program.
THURSDAY, OCTOBER 7

Poster Session
9:00 am (on-demand throughout conference)

Educational Sessions
10:00 am-11:20 am

**ED01: Exploiting Synthetic Lethality**
Session Cochairs: Eytan Ruppin, National Cancer Institute, Bethesda, MD, and Barbara Weber, Tango Therapeutics, Boston, MA
Channel A

10:00-10:05  Introduction
Barbara Weber, Tango Therapeutics, Boston, MA

10:05-10:25  Uncovering the principles that govern synthetic lethality in cancer
Christopher Lord, The Institute of Cancer Research, London, England

10:25-10:35  Q&A / Discussion

10:35-10:55  Synthetic lethality in microsatellite unstable cancers
André Nussenzweig, National Cancer Institute, Bethesda, MD

10:55-11:05  Q&A / Discussion

11:05-11:20  Panel Discussion
ED02: Novel Clinical Trial Designs and Development of Next-gen Investigators for Complex Anticancer Agents
Session Cochairs: Philippe L. Bedard, UHN Toronto General Hospital, Toronto, ON, Canada, and Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Channel B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:00-10:05 | Introduction
Philippe L. Bedard, UHN Toronto General Hospital, Toronto, ON, Canada |
| 10:05-10:23 | Early phase trials to establish proof of concept for adoptive cellular therapy for solid tumors
Prasad S. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, NY |
| 10:23-10:41 | Response adaptive randomization to prioritize promising investigational agents: I-SPY2
Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA |
| 10:41-10:59 | Real-world evidence to inform regulatory approval
Laleh Amiri-Kordestani, U.S. Food and Drug Administration, Silver Spring, MD |
| 10:59-11:20 | Panel Discussion
Prasad S. Adusumilli
Laleh Amiri-Kordestani
Philippe L. Bedard
Jacqueline Corrigan-Curay, U.S. Food and Drug Administration, Silver Spring, MD
Laura J. Esserman |

Break
11:20 am-11:35 am
Welcome and Opening Keynote Address
11:35 am-12:35 pm
Channel A

11:35-11:45  Welcome from Scientific Committee Cochairs
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
James L. Gulley, National Cancer Institute, Bethesda, MD
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

11:45-11:50  Introduction of Keynote Speaker
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

11:50-12:20  Lung cancer progression and detection: From aberrant basal cell to CT and blood screening
Samuel Janes, University College London, London, England

12:20-12:35  Q&A / Discussion

Break
12:35 pm-12:50 pm
Plenary Session 1: Tumor-targeted Conjugates: A Growing Family
12:50 pm-2:40 pm
Session Cochairs: Puja Sapra, AstraZeneca, Gaithersburg, MD, and Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland
Channel A

12:50-12:55  Introduction
  Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland

  Puja Sapra, AstraZeneca, Gaithersburg, MD

13:15-13:25  Q&A / Discussion

  Meredith McKean, Sarah Cannon Research Institute, Nashville, TN

13:45-13:55  Q&A / Discussion

13:55-14:15  XMT-2056: Tumor-targeted innate immune activation via a STING-agonist antibody drug conjugate
  Timothy B. Lowinger, Mersana Therapeutics, Cambridge, MA

14:15-14:25  Q&A / Discussion

14:25-14:40  Panel Discussion

Break
2:40 pm-2:55 pm
Concurrent Sessions 1-3
2:55 pm-4:30 pm

**CC01: Clinical Utility and Applications of New Computational Technologies**
Session Cochairs: Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada, and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX
Channel A

14:55-15:00  Introduction
Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX

15:00-15:18  An ML system for radiation therapy from lab to lives
Chris McIntosh, University of Toronto, Toronto, ON, Canada

15:18-15:36  Computational approaches to microsatellite instability analysis and TMB characterization
Elaine R. Mardis, Children’s Nationwide Hospital, Columbus, OH

15:36-15:54  Predicting outcomes of Phase III oncology trials with Bayesian mediation modeling
Brian P. Hobbs, The University of Texas at Austin, Austin, TX

15:54-16:02  The landscape of precision cancer combination therapy: A single-cell perspective*
Rahulsimham Vegesna, National Cancer Institute, Bethesda, MD

16:02-16:10  Novel algorithm discovers up to 70% more epitopes translated from non-coding regions in cold tumours *
Cedric Bogaert, myNEO, Ghent, Belgium

16:10-16:30  Panel Discussion
CC02: Drugs Targeting Metabolism
Session Cochairs: Stanley Lipkowitz, National Cancer Institute, Bethesda, MD, and Jean-Emmanuel Sarry, INSERM Cancer Research Center, Toulouse, France
Channel B

14:55-15:00  Introduction  
Stanley Lipkowitz, National Cancer Institute, Bethesda, MD

15:00-15:20  Mitochondrial determinants of response and resistance to therapies in acute myeloid leukemia  
Jean-Emmanuel Sarry, INSERM Cancer Research Center, Toulouse, France

15:20-15:30  Q&A / Discussion

15:30-15:50  Mitochondrial matrix Protease ClpP agonists suppress breast cancer stem cell function by downregulating multiple stem cell regulatory mechanisms  
Yoshimi E. Greer, National Cancer Institute, Bethesda, MD

15:50-16:00  Q&A / Discussion

16:00-16:10  Regulation of FASN expression through a novel IGF-1R-mTORC1-SRPK2-SRSF1 pathway*  
Bryan McClellan, University of Texas, Austin, TX

16:10-16:15  Q&A / Discussion

16:15-16:30  Panel Discussion
**CC03: Extracellular Vesicles as Therapeutic Targets**  
Session Cochairs: Toby T. Hecht, National Cancer Institute, Rockville, MD, and Jennifer C. Jones, National Cancer Institute, Bethesda, MD  
Channel C  

14:55-15:00  **Introduction**  
Toby T. Hecht, National Cancer Institute, Rockville, MD  

15:00-15:20  **Mechanisms of exosome driven immunoregulation of cancer progression**  
Robert H. Blelloch, University of California, San Francisco, CA  

15:20-15:30  **Q&A / Discussion**  

15:30-15:50  **Tumor derived exosomes: Their role in immune regulation and as biomarkers of cancer progression**  
Theresa L. Whiteside, University of Pittsburgh Cancer Institute, Pittsburgh, PA  

15:50-16:00  **Q&A / Discussion**  

16:00-16:10  **Exosome pathway inhibition as therapeutic strategy in colorectal cancer**  
Madalena N. Monteiro, VU University Medical Center, Amsterdam, Netherlands  

16:10-16:15  **Q&A / Discussion**  

16:15-16:30  **Panel Discussion**  

**Break**  
4:30 pm-4:45 pm  

*Keynote Address*  
4:45 pm-5:35 pm  
Channel A  

16:45-16:50  **Introduction of Keynote Speaker**  
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada  

16:50-17:20  **CRISPR and gene modification for cancer therapeutics (focus on the future applications of this technology)**  
Jennifer A. Doudna, UC Berkeley, Berkeley, CA  

17:20-17:35  **Q&A / Discussion**
FRIDAY, OCTOBER 8

Plenary Session 2: New Drugs on the Horizon I
10:00 am-11:40 am
Session Cochairs: James L. Gulley, National Cancer Institute, Bethesda, MD, and Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Channel A

10:00-10:05  Introduction
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

10:05-10:20 Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: Update from the registrational phase 2 TRIDENT-1 trial*
Benjamin Besse, Institut Gustave Roussy, Villejuif, France

10:20-10:25  Q&A / Discussion

10:25-10:40  First results of RLY-4008, a potent and highly selective FGFR2 inhibitor in a first-in-human study in patients with FGFR2-altered cholangiocarcinoma and multiple solid tumors*
Lipika Goyal, Massachusetts General Hospital, Boston, MA

10:40-10:45  Q&A / Discussion

10:45-11:00  Phase Ia/Ib dose-escalation study of ABL001 (CTX-009, Bispecific antibody targeting DLL4 and VEGF-A) as a single agent in patients with advanced solid tumors*
Jeeyun Lee, Samsung Medical Center, Seoul, Korea

11:00-11:05  Q&A / Discussion

11:05-11:20  BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases*
Matthew C. Lucas, Black Diamond Therapeutics, Cambridge, MA

11:20-11:25  Q&A / Discussion

11:25-11:40  Panel Discussion

Break
11:40 am-12:00 pm
Plenary Session 3: Bispecific T-Cell Engagers and Next-Gen CAR T Therapies: Pros and Cons of These Strategies
12:00 pm-2:00 pm
Session Cochairs: Kapil Dhingra, KAPital Consulting LLC, Sparta, NJ and Jeffrey A. Moscow, National Cancer Institute, Bethesda, MD
Channel A

12:00-12:05 Introduction
Kapil Dhingra, KAPital Consulting LLC, Sparta, NJ

12:10-12:30 Bispecific T cell engagers (TCEs) for treatment of solid tumors: Challenges and opportunities
Patrick A. Baeuerle, MPM Capital LLC, Cambridge, MA

12:30-12:50 Title to be announced (CAR-Ts for treatment of solid tumors: Opportunities and challenges)
Martin Pule, University College London, London, England

12:50-13:10 Bispecific gamma-delta T-cell engagers for treatment of cancer
Hans J. van der Vliet, Amsterdam University Medical Center, Amsterdam, Netherlands

13:10-13:55 Panel Discussion

Break
1:55 pm-2:10 pm
Concurrent Sessions 4-6
2:10 pm-3:45 pm

**CC04: Novel Precision Medicine Combination Trials**
Session Cochairs: James H. Doroshow, National Cancer Institute, Bethesda, MD, and Elena Garralda, Vall D'Hebron Institute of Oncology, Barcelona, Spain
Channel A

14:10-14:15  Introduction
Elena Garralda, Vall D'Hebron Institute of Oncology, Barcelona, Spain

14:15-14:35  Combination therapy and the search for synergy via greater precision
Peter K. Sorger, Harvard Medical School, Boston, MA

14:35-14:45  Q&A / Discussion

14:45-15:05  Novel rare tumor models to assess new drug combinations
James H. Doroshow, National Cancer Institute, Bethesda, MD

15:05-15:15  Q&A / Discussion

15:15-15:25  First-in-Human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3-related inhibitor (ATRI) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations*
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

15:25-15:30  Q&A / Discussion

15:30-15:45  Panel Discussion
CC05: Preclinical Models and Predictive Value
Session Cochairs: Lori S. Friedman, ORIC Pharmaceuticals, South San Francisco, CA, and Zoë Weaver Ohler, Frederick National Laboratory for Cancer Research, Frederick, MD
Channel B

14:10-14:15 Introduction
Zoë Weaver Ohler, Frederick National Laboratory for Cancer Research, Frederick, MD

14:15-14:35 Supporting precision oncology through non-germline mouse models
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

14:35-14:45 Q&A / Discussion

14:45-15:05 Approaches to modulate tumor cell plasticity in combination with immunotherapy
Claudia Palena, National Cancer Institute, Bethesda, MD

15:05-15:15 Q&A / Discussion

15:15-15:35 Insights into therapeutic resistance from mouse models of lung cancer
Katerina A. Politi, Yale Cancer Center, New Haven, CT

15:35-15:45 Q&A / Discussion

15:45 Closing Comments
**CC06: Radiopharmaceuticals Coming of Age**  
Session Co-chairs: Beverly A. Teicher, National Cancer Institute, Bethesda, MD and Rebecca K.S. Wong, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada  
Channel C

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:10-14:15</td>
<td>Introduction</td>
<td>Beverly A. Teicher, National Cancer Institute, Bethesda, MD</td>
</tr>
<tr>
<td>14:15-14:35</td>
<td>Radiopharmaceuticals and their future in cancer care</td>
<td>Charles A. Kunos, University of Kentucky College of Medicine, Lexington, KY</td>
</tr>
<tr>
<td>14:35-14:45</td>
<td>Q&amp;A / Discussion</td>
<td></td>
</tr>
<tr>
<td>14:45-15:05</td>
<td>Toward molecularly guided radiotherapy: Accelerated through science and technology</td>
<td>David A. Jaffray, The University of Texas MD Anderson Cancer Center, Houston, TX</td>
</tr>
<tr>
<td>15:05-15:15</td>
<td>Q&amp;A / Discussion</td>
<td></td>
</tr>
<tr>
<td>15:15-15:25</td>
<td>Identifying therapeutic options for patients with advanced prostate cancer through genes in liquid biopsies*</td>
<td>Seta Derderian, McGill University Health Center, Montreal, QC, Canada</td>
</tr>
<tr>
<td>15:25-15:30</td>
<td>Q&amp;A / Discussion</td>
<td></td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Break**  
3:45 pm-4:00 pm
AACR Chemistry in Cancer Research (CICR) Working Group Town Hall
4:00 pm-5:15 pm
Channel A

16:00-16:05  Introduction and overview of 2021-2022 CICR Working Group programs and activities
Mary M. Mader, MM Molecular Pharma Consulting, Melrose, MA
2021-2022 Chair-elect, AACR Chemistry in Cancer Research Working Group

16:05-16:20  Perspective on bivalent degraders
Alessio Ciulli, University of Dundee, Dundee, United Kingdom

16:20-16:35  Perspective on molecular glue degraders
Eric Fischer, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

16:35-16:50  A complex task: Perturbing oncogenic transcriptional networks with small molecules
Angela Koehler, Broad Institute of Harvard and MIT, Cambridge, MA

16:50-17:15  Panel Discussion
SATURDAY, OCTOBER 9

Plenary Session 4: DNA Damage Response Beyond PARP
10:00 am-11:50 am
Session Cochairs: Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom and Ioannis Gounaris, Merck-Serono Ltd., Feltham, United Kingdom
Channel A

10:00-10:05  Introduction
            Ioannis Gounaris, Merck-Serono Ltd., Feltham, United Kingdom

10:05-10:25  Preclinical development of novel DNA repair inhibitor combinations
            Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA

10:25-10:35  Q&A / Discussion

10:35-10:55  Targeting the DDR beyond PARP inhibitors: Novel agents and rational combinations
            Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

10:55-11:05  Q&A / Discussion

11:05-11:25  Patient identification for DDRi trials
            Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

11:25-11:35  Q&A / Discussion

11:35-11:50  Panel Discussion

Break
11:50 am-12:05 pm
Plenary Session 5: Drugging Difficult Targets
12:05 pm-1:55 pm
Session Cochairs: Fiona H. Blackhall, University of Manchester, Manchester, England and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Channel A
12:05-12:10  Introduction
Fiona H. Blackhall, University of Manchester, Manchester, England
12:10-12:25  Mechanisms of acquired resistance to KRAS G12C inhibitors: Opportunities and challenges
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
12:25-12:30  Q&A / Discussion
12:30-12:50  Discovery and characterization of MRTX1133, a selective non-covalent inhibitor of KRASG12D
James G. Christensen, Mirati Therapeutics, San Diego, CA
12:50-12:55  Q&A / Discussion
12:55-13:15  Discovery and development of RAS(ON) inhibitors beyond KRAS G12C
Stephen Kelsey, Revolution Medicines, Inc., Redwood City, CA
13:15-13:20  Q&A / Discussion
13:20-13:30  A phase 1b study evaluating the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-mutated solid tumors*
Suresh Ramalingam, Emory University School of Medicine, Atlanta, GA
13:30-13:40  A phase 1b study evaluating the combination of sotorasib, a KRAS G12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)*
David Gandara, University of California Davis Comprehensive Cancer Center, Sacramento, CA
13:40-13:55  Panel Discussion
Break
1:55 pm-2:10 pm
Concurrent Sessions 7-9
2:10 pm-3:45 pm

**CC07: Targeting Molecular Residual Disease (MRD) with ctDNA Technologies**
Session Cochairs: Benjamin Besse, Institut Gustave Roussy, Villejuif, France, and Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Channel A

14:10-14:15  Introduction
Benjamin Besse, Institut Gustave Roussy, Villejuif, France

14:15-14:35  Clinical application of ctDNA in the MRD setting
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

14:35-14:45  Q&A / Discussion

14:45-15:05  Biomarkers for precision oncology
Alain Thierry, Institut de Recherche en Cancérologie de Montpellier, Montepellier, France

15:05-15:15  Q&A / Discussion

15:15-15:25  Whole exome and whole genome methylation sequencing of low-input cfDNA to implement precision medicine in metastatic castration resistant prostate cancer*
Raju Kandimalla, Bristol Myers Squibb, San Diego, CA

15:25-15:30  Q&A / Discussion

15:30-15:45  Panel Discussion
CC08: Tumor Microbiome
Session Cochairs: Tim F. Greten, National Cancer Institute, Bethesda, MD, and Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France
Channel B

14:10-14:15  Introduction
    Tim F. Greten, National Cancer Institute, Bethesda, MD

14:15-14:35  The role of the tumor microbiome in cancer
    Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

14:35-14:45  Q&A / Discussion

14:45-15:05  Microbiota, immunity, and cancer
    Maria Rescigno, Humanitas University, Milan, Italy

15:05-15:15  Q&A / Discussion

15:15-15:45  Panel Discussion
CC09: Protein-Protein Inhibitors (PPI) in Hematologic Malignancies: Challenges and Promise
Session Cochairs: Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, MI, and Tim Somervaille, Cancer Research UK Manchester Institute, Manchester, England
Channel C

14:10-14:15  Introduction
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, MI

14:15-14:35  Inosital transporter SLC5A3 is a synthetic lethal dependency Acute Myelod Leukemia
Christopher R. Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

14:35-14:45  Q&A / Discussion

14:45-15:05  Targeting protein-protein interactions through induced protein degradation
Shaomeng Wang, University of Michigan Rogel Cancer Center, Ann Arbor, MI

15:05-15:15  Q&A / Discussion

15:15-15:25  Targeting BCL-XL/BCL-2 by PROTAC 753b effectively eliminates AML cells and enhances efficacy of chemotherapy by targeting senescent cells*
Yannan Jia, The University of Texas MD Anderson Cancer Center, Houston, TX

15:25-15:30  Q&A / Discussion

15:30-15:45  Panel Discussion

Break
3:45 pm-4:00 pm
Plenary Session 6: New Drugs on the Horizon II
4:00 pm-5:40 pm
Session Cochairs: James L. Gulley, National Cancer Institute, Bethesda, MD, and Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom
Channel A

16:00-16:05  Introduction
James L. Gulley, National Cancer Institute, Bethesda, MD

16:05-16:20  A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors*
Eugen Leo, CatalYm GmbH, Planegg-Martinsried, Germany

16:20-16:25  Q&A / Discussion

16:25-16:40  Discovery of TAS0953/HM06, a novel next generation RET-specific inhibitor capable of inhibiting RET solvent front mutations*
Isao Miyazaki, Taiho Pharmaceutical Company, Tukuba, Japan

16:40-16:45  Q&A / Discussion

16:45-17:00  Discovery of mutant-selective PI3Ka and isoform-selective FGFR3 inhibitors: Insights from the Loxo Oncology at Lilly Discovery Model
David M. Hyman, Loxo Oncology at Lilly, Stamford, CT

17:00-17:05  Q&A / Discussion

17:05-17:20  ST101, a peptide targeting oncogenic transcription factor C/EBPB: Initial safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data from an ongoing phase 1 dose escalation study in patients with advanced metastatic solid tumors*
Nehal J. Lakhani, START Midwest, Grand Rapids, MI

17:20-17:25  Q&A / Discussion

17:25-17:40  Panel Discussion
SUNDAY, OCTOBER 10

Plenary Session 7: HER2-directed Therapies - Dedicated to the Memory of José Baselga
10:00 am-11:50 am
Session Cochairs: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, and Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium
Channel A

10:00-10:05  Introduction
Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, and Martine J. Piccart, Institut Jules Bordet, Brussels

10:05-10:25  Tailoring treatment in HER2+ breast cancer: Remarkable advances, transformed outcomes
Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

10:25-10:35  Q&A / Discussion

10:35-10:55  HER2 heterogeneity implications for biology, tumor evolution, and treatment
Aleix Prat, Hospital Clinic, Barcelona, Spain

10:55-11:05  Q&A / Discussion

11:05-11:25  Novel treatment approaches for HER2-positive breast cancer
Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA

11:25-11:35  Q&A / Discussion

11:35-11:50  Panel Discussion

Break
11:50 am-12:05 pm
Plenary Session 8: Non T Lymphocyte Immune Effector Cell Therapies
12:05 pm-1:55 pm
Session Cochairs: Rosandra N. Kaplan, National Cancer Institute, Bethesda, MD, and Frederick L. Locke, Moffitt Cancer Center, Tampa, FL
Channel A

12:05-12:10  Introduction
Frederick L. Locke, Moffitt Cancer Center, Tampa, FL

12:10-12:28  Memory-like NK cell therapy in the treatment of advanced malignancies
Rizwan Romee, Dana-Farber Cancer Institute, Boston, MA

12:28-12:33  Q&A / Discussion

12:33-12:51  Targeting ovarian cancer mediated suppression of NKT cell activation
Tonya J. Webb, University of Maryland School of Medicine, Baltimore, MD

12:51-12:56  Q&A / Discussion

12:56-13:14  Myeloid cells and therapeutic opportunities for microenvironmental regulation
Rosandra N. Kaplan, National Cancer Institute, Bethesda, MD

13:14-13:19  Q&A / Discussion

13:19-13:37  Chimeric antigen receptor macrophages for the treatment of solid tumors
Saar Gill, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

13:37-13:42  Q&A / Discussion

13:42-13:55  Panel Discussion

Break
1:55 pm-2:10 pm
Plenary Session 9: Protein Degraders and Molecular Glues  
2:10 pm-4:00 pm  
Channel A

14:10-14:15  Introduction  
Susan M. Galbraith, AstraZeneca, Cambridge, England

14:15-14:35  PROTACs and targeted protein degradation: A new therapeutic modality  
Craig M. Crews, Yale University, New Haven, CT

14:35-14:45  Q&A / Discussion

14:45-15:05  How do cullin-RING ligases ubiquitylate structurally diverse substrates?  
Brenda A. Schulman, Max Planck Institute of Biochemistry, Martinsried, Germany

15:05-15:15  Q&A / Discussion

15:15-15:35  Targeted protein degradation for the treatment of cancer  
Benjamin L. Ebert, Dana Farber Cancer Institute, Boston, MA

15:35-15:45  Q&A / Discussion

15:45-16:00  Panel Discussion

Break
4:00 pm-4:15 pm

Closing Session: What is the Biggest Roadblock in Anticancer Drug Development in the Next Decade and What Can be done to Mitigate?  
4:15 pm-5:45 pm  
Moderator: Jean-Charles Soria, Amgen, Thousand Oaks, CA

Panelists:
Emiliano Calvo, START Madrid, Madrid, Spain
Levi A. Garraway, Genentech, South San Francisco, CA
James L. Gulley, National Cancer Institute, Bethesda, MD
Maria T. Koehler, REPARE Therapeutics, Boston, MA
Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom
Tatiana M. Prowell, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, U.S. Food and Drug Administration, Baltimore, MD
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain